S&P Futures
4,160.25+4.75(+0.11%)Dow Futures
33,977.00+19.00(+0.06%)Nasdaq Futures
13,927.75+30.50(+0.22%)
Lantheus Holdings, Inc. (LNTH)
Chart Events
Performance Outlook
| Previous Close | 21.70 |
| Open | 21.73 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 800 |
| Day's Range | 21.16 - 21.74 |
| 52 Week Range | 10.52 - 21.99 |
| Volume | 383,060 |
| Avg. Volume | 583,246 |
| Market Cap | 1.43B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings Date | Feb 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.40 |
- Business Wire
Lantheus Expands R&D Leadership Team with Key New Hires
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko. Both report directly to Lantheus’ Chief Medical Officer, Istvan Molnar, MD.
- Business Wire
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced that Michael P. Duffy, Senior Vice President, Law and Public Policy and General Counsel will retire from Lantheus on June 4, 2021 after more than 13 years with Lantheus. Mr. Duffy will be retained in an advisory capacity. His responsibilities will be assumed by Daniel Niedzwiecki, who has been with the Company since 2013 and will report directly to Mary Anne Heino, President and CEO.
- Benzinga
Lantheus Buys Rights To Fibroblast Activation Protein Targeting Imaging Biomarker
Lantheus Holdings Inc (NASDAQ: LNTH) has acquired the exclusive worldwide rights to develop, manufacture and commercialize NTI-1309, a PET oncology imaging agent from Noria Therapeutics Inc. NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting oncology implications. FAP is overexpressed in the tumor microenvironment, specifically in tumor-associated fibroblasts, which modulates tumor progression and immune response. Under terms of the agreement, Noria will drive the early clinical development of NTI-1309. Upon completing the Phase 1 study, NTI-1309 will be integrated into Lantheus's portfolio of imaging biomarkers. The transaction's terms include an upfront license and development fee to Noria, certain milestone payments, and royalties if NTI-1309 is commercialized. Price Action: LNTH shares are up 10.1% at $21.69 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaForma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease StudyTiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
